PCN35 A COST UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER IN GREECE (PRELIMINARY RESULTS)
Nov 1, 2005, 00:00
10.1016/S1098-3015(10)67273-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)67273-7/fulltext
Title :
PCN35 A COST UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER IN GREECE (PRELIMINARY RESULTS)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67273-7&doi=10.1016/S1098-3015(10)67273-7
First page :
Section Title :
Open access? :
No
Section Order :
504